Você procurou por: ivermectin (Inglês - Maltês)

ivermectin
ivermectin

ivermectin 18.7 mg/ g
pejst ivermectin abjad omoġenju 18. 7 mg/ g

praziquantel or ivermectin (for certain worm infections);
praziquantel jew ivermectin (għal ċerti infezzjonijiet bid-dud);

equimectin 12mg/ g oral gel for horses contains ivermectin.
equimectin 12mg/ g ġel orali għaż- żwiemel fih ivermectin.

ivermectin, due to a reduction of ivermectin plasma levels.
ivermectin, minħabba tnaqqis fil-livelli ta’ ivermectin fil-plażma.

ivermectin-containing products are widely used in these species.
prodotti li fihom l- ivermectin jintużaw ħafna f’ dawn l- ispeċi.

ivermectin is a member of the macrocyclic lactone class of endectocides.
ivermectin huwa membru tal- klassi tal- macrocyclic lactone ta 'l- endektoċidi.

ivermectin-sensitive collie dogs tolerated up to 5 times the recommended dose without any adverse effects.
klieb tar- razza tal- collie sensitivi għall- vermettina ttolerraw id- doża rrikommandata sa 5 darbiet mingħajr affetti avversarji.

ecomectin 18.7 mg/ g oral paste for horses is a white homogenous paste containing ivermectin.
ecomectin 18. 7 mg/ g pejst orali għaż- Żwiemel huwa pejst abjad omoġenju li fih ivermectin.

one syringe division of paste per 100 kg body weight (based on a recommended dosage of 200 microgram ivermectin per kg body weight).
marka waħda ta ’ fuq is - siringa ta’ pejst għal kull 100 kg piż korporju (abbażi tad- doża irrakomandata ta ’ 200 mikrogramma ivermectin għal kull kg ta ’ piż korporju).

in humans it is known that itraconazole can inhibit the metabolism of medicinal products that are substrates for cytochrome 3a isoenzymes, for example, chloramphenicol, ivermectin or methylprednisolone.
fil-bnedmin huwa magħruf li itraconazole jista' jinibixxi l-metaboliżmu ta’ prodotti mediċinali li huma substrati għal isoenzimi taċ-ċitokromju 3a, pereżempju, chloramphenicol, ivermectin jew methylprednisolone.

co-treatment with other drugs that are p-glycoprotein substrates/ inhibitors (for example, ivermectin and other antiparasitic macrocyclic lactones,
trattament flimkien ma ’ mediċina oħra li hija substrat/ inibitur tal- p- glajkoprotejn (eż. ivermektina, u lattoni makroċikliċi oħra kontra l- parassiti, eritromiċina, prednisolon u ċiklosporin) jista ’ jirriżulta f’ effetti farmakokinetiċi mediċinali.

ivermectin-sensitive collie dogs tolerated up to 5 times the recommended dose repeated at monthly intervals without any adverse effects, but the safety of application at weekly intervals has not been investigated in ivermectin-sensitive collie dogs.
klieb tar-razza tal-collie sensitivi għall-vermettina ttolerraw id-doża rrakkomandata sa 5 darbiet ripetuta f’intervalli ta’ kull xahar mingħajr affetti avversi, iżda s-sigurtà tal-applikazzjoni f’intervalli ta’ ġimgħa ma ġietx investigata fil-klieb tar-razza collie sensittivi għal ivermectin.

co-treatment with other drugs that are p-glycoprotein substrates/inhibitors (for example, ivermectin and other antiparasitic macrocyclic lactones, erythromycin, prednisolone and cyclosporine) could give rise to pharmacokinetic drug interactions.
trattament flimkien ma’ mediċini oħra li huma substrat/inibitur għal p-glajkoprotejn (eż. ivermektin, u lattoni makroċikliċi oħra kontra l-parassiti, eritromiċina, prednisolon u ċiklosporin) jistgħu jirriżultaw f’effetti farmakokinetiċi fuq xulxin.